The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.

PALO ALTO, CA, UNITED STATES, January 7, 2026 /EINPresswire.com/ -- Latica (formerly Lynx.MD), a leader in medical data ...

A real world systematic review and meta-analysis found tildrakizumab improved plaque psoriasis severity and quality of life ...

Shares of Alumis ALMS surged 95.3% on Jan. 6, after the company announced positive top-line data from its two phase III ...

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

About 7.5 million Americans have psoriasis. But, despite psoriasis being a fairly common skin condition, it's often misunderstood. In case you're not familiar with it, psoriasis is a condition that ...

Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

Psoriasis severity and quality of life appeared to improve with weight-loss interventions in a systematic review.

Methotrexate is a strong medicine. The FDA approved it to treat adults with severe, disabling psoriasis that cannot be controlled with medicine applied to the skin or light treatments. Methotrexate ...